Country: Malta
Language: English
Source: Medicines Authority
chlorhexidine digluconate 0.2 % (w/v)
Beecham Group PLC
A01AB03
chlorhexidine digluconate
oromucosal solution
Authorised
2006-03-24
PAGE 1 OF 4 PAGE 2 OF 4 PAGE 1 OF 4 PAGE 2 OF 4 Read the complete document
Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Corsodyl Mint Mouthwash 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Chlorhexidine Digluconate 0.2% w/v (equivalent to Chlorhexidine Digluconate Solution Ph Eur 1.0% v/v) 3. PHARMACEUTICAL FORM Oromucosal solution 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For inhibition of the formation of dental plaque. As an aid in the treatment and prevention of gingivitis and in the maintenance of oral hygiene, particularly in situations where toothbrushing cannot be adequately employed (eg following oral surgery, in mentally or physically handicapped patients). Also for use in a post-peridontal surgery or treatment* regimen to promote gingival healing. *NB: Use as part of a post-periodontal treatment regimen has only been adequately studied over the short term and following standard root surface instrumentation. It is useful in the management of aphthous ulceration and oral candidal infections (eg denture stomatitis and thrush). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults: Thoroughly rinse the mouth for about one minute with 10 ml twice daily. In the dental surgery the patient should be instructed to rinse the mouth for one minute prior to treatment. Corsodyl is incompatible with anionic agents which are usually present in conventional dentifrices. These should therefore be used before Corsodyl (rinsing the mouth between applications) or at a different time of day. For the treatment of gingivitis a course of about one month is advisable although some variation in response is to be expected. In the case of aphthous ulceration and oral candidal infections treatment should Read the complete document